Early day motion tabled by primary sponsor Paul Flynn (Labour), on Thursday, 5 February 2004, in the House of Commons. It is signed by 64 members in total.

---

SEROXAT

That this House expresses concern at the tragic deaths associated with the anti-depressant drug Seroxat and the news that GlaxoSmithKline suppressed news of two 1998 studies that demonstrated that the drug was no more effective than placebos; notes with alarm the Department of Health's view that Seroxat can make the symptoms of depression more severe and the decision of a court that Seroxat was responsible for a change in the behaviour of a man who took his own life and that of his family; and calls for a full investigation of the conduct of GlaxoSmithKline who appear to have put their private greed before public safety.

---

Secondary information

Type

Early day motion

Reference

568 

Session

2003-04

Subjects

Disclosure of information Death Prescription drugs Safety Research Paroxetine GlaxoSmithKline

Link

View this Early day motion on www.parliament.uk